# Geneseeq Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneseeq-tech

- Industry: Healthcare
- Headquarters: Nanjing, China
- Website: www.geneseeq.com
- Total disclosed funding: $122M
- Latest round: Series D (Dec 24, 2019)
- Investors on record: 14

## About

Founded in 2008 and based in Nanjing, China, Geneseeq operates as a cancer diagnostic company that provides cancer treatments based on the comprehensive systematic analyses of patients' genomic mutations.

## Funding rounds

- Series D, Dec 24, 2019, $114M — SB China Venture Capital, Lilly Asia Ventures, Huatai Securities, E Fund Management Co.,Ltd, Everest VC, China Reform Holdings, Xiamen C&D Emerging Industry Equity Investment, Tianqin Junze Capital, Winfast Holding
- Series D, Jun 1, 2018 — Beyond Capital
- Series C, Nov 1, 2017, $7.5M — DNV Capital
- Series C, Jul 20, 2017 — Cowin Capital, Huatai Securities, Industrial Innovation Capital Management, Boyuanhongsheng

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series C
- Huatai Securities — Series C, Series D
- Industrial Innovation Capital Management — Series C
- Boyuanhongsheng — Series C
- DNV Capital (https://capitalatlas.ai/funds/dnv-capital) — Series C
- Beyond Capital — Series D
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series D
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series D
- E Fund Management Co.,Ltd — Series D
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series D
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series D
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series D
- Tianqin Junze Capital (https://capitalatlas.ai/funds/tianqin-junze-capital) — Series D
- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series D